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Despite past decades of steady advances in reducing severity of Malaria, statistics show that 
the disease continues to pose a serious threat to human health. Previous successes in 
development of antimalarial drugs from medicinal plants have fuelled research in this area. 
However, antimalarial studies to fractionate extracts from such plants have progressed 
slowly. This study reports antimalarial potential of fractions from Lippia kituiensis Vatke, for 
the first time. Column chromatography was used during fractionation. Antiplasmodial assays 
against chloroquine-sensitive (D6) and resistant (W2) Plasmodium strains was done using 
hypoxanthine incorporation assay. A colorimetric assay was done to assess cytotoxicity of 
fractions against the Vero cell line. Obtained fractions exhibited varied inhibitory 
concentrations (IC50); with the most efficacious being, Lk-5 (19.45 ± 6.20 μg/ml), Lk-3 
(30.43 ± 0.68 μg/ml), Lk-4 (30.82 ± 18.01 μg/ml), and Lk-6 (36.53 ± 14.42 μg/ml) against 
D6. Generally, lower activity against W2 was obtained with the most active being Lk-4 
(24.18±2.50 μg/ml), and Lk-5 (24.42±5.95 μg/ml), while chloroquine (positive control) 
exerted IC50 of 77.86±4.09 ng/ml (W2) and 15.71±6.49 ng/ml (D6) respectively. Fraction 
LK-4 was the most cytotoxic showing cytotoxic concentration of 46.26 μg/ml. When tested 
in mice, fractions suppressed Plasmodium berghei significantly compared to the negative 
control with Lk-3 being the most efficacious (80.01±1). Due to substantive efficacy, GC-MS 
was done on Lk-3 revealing 8 compounds where three have previously been ascribed to 
antimalarial activity and other pharmacological effects. This study adds to present knowledge 
of antimalarial efficacy of L. kituiensis and provides basis for further work to be done on 
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1.1 Background of the Problem 
Malaria remains the most prevalent and fatal-vector-borne disease (Friesen et al., 2010). In 
2016 alone, the World Health Organization (WHO) reported approximately 216 million cases 
of malaria globally. This was more than the 211 million cases reported in 2015. Notably, 
African continues to suffer a disproportionately higher burden of the disease (90% of the 
global cases). Although there has been a significant decline in the global cases of Malaria 
over the last decade, recent reports indicate that progress has stalled particularly in the period 
2010-2016 (WHO Malaria Report, 2017).  
Malaria is spread by the Anopheles genus female mosquitoes infected with Plasmodium spp. 
Human malaria can be caused by Plasmodium falciparum, P. ovale, P. vivax, P. malariae and 
P. knowlesi (Singh et al., 2004; Van Hellemond et al., 2009). Humans make excusive 
mammalian hosts for  P. falciparum and P. vivax, the most common species of plasmodia and 
are responsible for the largest transmission of the disease (Phillips et al., 2017).  
The recent discovery of malaria as a zoonotic disease due to P. knowlesi transmission, poses 
obvious complications for elimination (Imwong et al., 2011). With currently no approved 
vaccine, vector control and chemotherapy are the mainstay methods of malaria control (Chen 
et al., 2018). Artemisinin is the cornerstone of malaria chemotherapy (O’Neill et al., 2010). 
However, worrying concerns of failure attributable to resistance have been published 
(Landier et al., 2018); highlighting a pressing need to find alternative treatment options 
(Pinheiro et al., 2018). Furthermore, the discovery of new effective, well tolerated and safe 
antimalarial drugs remains an uphill task (Pereira et al., 2011). The hunt for new anti-malarial 
compounds, particularly from plants historically used for malaria treatment, is rife (Batista et 
al., 2009). This is because plants are a rich source of potential leads having new mechanisms 
of action (Bero et al., 2009).  
The therapeutic efficacy of two antimalarial drugs derived from plants, (quinine and 
artemisinin), have led to global consensus that plants possess immense potential as sources 




Lippia belongs to the family Verbenaceae; a genus of flowering plants known for its 
characteristic aromaticity from their essential oil (Arthur et al., 2011). With approximately 
200 species, the family consists of shrubs, herbs, and small trees. These species are primarily 
distributed throughout tropical African countries and South and Central American territories 
(Pascual et al., 2001). Several studies have reported pharmacological effects of lippia 
including antimalarial, antimicrobial, antifungal, analgesic, antipyretic, anti-inflammatory 
antispasmodic and larvicidal activities (Stashenko et al., 2013).  
Lippia kituiensis Vatke is used by local communities in Tanzania to treat malaria. To the best 
of our understanding, the current study reports antimalarial efficacy of fractions obtained 
from L. kituiensis for the first time. This is a subsequent study guided by previous reports 
showing a significant chemo-suppressive activity (95.19%)  of total extracts of the plant 
against Plasmodium berghei (Mzena et al., 2018). 
1.2 Statement of the Problem 
Despite of there being extensive knowledge of etiology and pathogenesis, malaria continues 
to be a devastating health concern especially in Africa. According to the World Health 
Organization, the African continent contains a disproportionately high share of the 
worldwide protozoal infection. In 2015 alone, 90% of malaria cases and 92% of global 
malaria deaths were recorded in the region (WHO, 2017). Recent reports indicate that 
Plasmodium species have developed resistance to Artemisinin, the mainstay antimalarial 
drug. 
In view of these challenges, the need to seek alternative therapies to manage malaria cannot 
be overemphasized. Plants possess great potential for use in treatment of the disease. This is 
because of their long history of successful traditional use in developing countries. In order 
to validate the effectiveness of such herbal remedies, several scientific studies have been 
done.  This study sought to screen fractions from organic extracts of L. kituiensis against 
plasmodium species. In vitro cytotoxicity and phytochemical constituents of the fractions 






1.3 Rationale for the Study 
There is evidently a substantial interest in natural products and the possibility for their role as 
new antimalarials. This is not a new departure considering that three of the mainstay malaria 
treatment come from natural products: quinine, lapachol (which led to atovaquone) and 
artemisinin. The traditional utilization of Lippia kituiensis to treat malaria in Tanzania is rife. 
This makes the plant a very important resource with the current scientific interest in 
exploration of novel antimalarial drugs from plants. This study therefore sought to fractionate 
organic extracts of Lippia kituiensis which has previously been shown to possess strong 
antimalarial activity.  
1.4 Objectives 
1.4.1 General Objective 
To fractionate Lippia kituiensis organic extracts and determine antimalarial efficacy and 
phytochemical constituents of the fractions. 
1.4.2 Specific Objectives 
i) To investigate in vitro and in vivo antiplasmodial activity of fractions of L. 
kituiensis. 
ii) To evaluate cytotoxic effects of fractions of L. kituiensis. 
iii) To determine phytochemical constituents of fractions of L. kituiensis. 
1.5 Research Questions 
This study sought to answer the following questions: 
i) Do fractions of L. kituiensis possess anti-malaria activity? 
ii) What are the cytotoxic levels of fractions of L. kituiensis? 
iii) What are the phytochemical constituents that can be associated with antimalarial 
activity of L. kituiensi? 
1.6 Significance of the Study 
This study pioneers the search for novel antimalarial ‘leads’ from L. kituiensis; a medicinal 




This study also illustrates secondary metabolites in different fractions that can be associated 
with their antimalarial efficacy. In this study, the compounds associated with antimalarial 
efficacy of plant fractions are highlighted, paving the way for further research to be done to 
isolate the identified compound(s). 
Preliminary in vitro safety profile of fractions from L. kituiensis have been made evidenced 
in this study. Although further studies are needed on this, the current study has shown that 
the toxicity of the extracts from the plant by far exceed the therapeutic levels hence the 
traditional use to manage malaria 
In addition, this research adds to the current knowledge on the effectiveness of the plant and 
thus validates its ethnobotanical value for local communities. This data can extensively 
contribute to policy development towards the channeling of safe and efficacious medicinal 
plants to primary healthcare, particularly in Malaria management.  
1.7 Delineation of the Study 
Previous studies by Mzena et al. ( 2018) demonstrated significant antimalarial activity of 
total extracts of L. kituiensis leading to this study. The samples were harvested on 13th March 
2018 and transported to NM-AIST on 14th March 2018 from 8-11 am. Samples of fresh aerial 
parts of the plant were harvested sustainably from Ugweno village in Kilimanjaro region, 
Northern Tanzania (3° 39’ 0” South and 37° 39’ 0”), where they are traditionally used to treat 
Malaria. The plant was authenticated by a resident herbalists in the presence of a professional 
taxonomist. Voucher specimen was taken and deposited at the Nelson Mandela African 
Institute of Science and Technology and assigned specimen number LKV-160-2018. Soil and 
other contaminants were washed off using cold water. The plant material was dried under 
shade till complete dryness, milled into fine powder and packed in manila bags. The 
powdered plant material was transported to the Kenya Medical Research Institute, Nairobi 






2.1 Epidemiology of Malaria 
Despite current advances in science and the existing knowledge on pathogenesis, Malaria 
continues to cause sicknesses and death (Cox, 2010). Whereas the epidemiology of the 
disease varies geographically the precise numbers may be questionable and sometimes 
underreported with 395 000  estimated deaths in Africa in 2015  (Nkumama et al., 2017). In 
2017, an estimated 435 000 deaths occurred due to Malaria (WHO Malaria Report, 2018). 
Other than claiming hundreds of thousands of lives of young children yearly, experts 
observe that  malaria may have killed half of the human generation (Whitfield, 2002). The 
main symptoms of severe Malaria include; metabolic acidosis, renal failure, anaemia, acute 
kidney injury, cerebral malaria, pulmonary oedema, hypoglycaemia, hypertension and shock 
(Trampuz et al., 2003). Given the wide range of conceivable manifestations, it isn't clear 
what aspect(s) of the malady can and ought to be measured to monitor the changing 
epidemiology accurately (Koram & Molyneux, 2007). Sometimes malaria is said to be 
symptomless, but may be better termed chronic (Chen et al., 2016). The importance of the 
disease is further demonstrated by the lack of development potential for malaria-endemic 
countries, the impact on their healthcare systems and their detrimental effects on economic 
growth (Sicuri et al., 2013). The severity of the disease has however declined significantly 
due to combined efforts by multi-sectoral agencies over time, leading to reduced infection 
rates up to half and 4.3 million lives saved (Tanner et al., 2013).  
2.2 Malaria situation in Tanzania 
While malaria estimates in Tanzania are contradictory, reports show that the country has 
the third largest malaria-risk population in Africa, with 93% of people in mainland 
Tanzania and the entire population in Zanzibar living in endemic areas of malaria. In 2017, 
approximately 5.9 million clinical cases of malaria were reported on mainland Tanzania. 
(President's Malaria Initiative, 2018). Transmission patterns of the disease have been 
mapped as approximately 20 % of the country experiencing seasonal malaria and another 
20 percent facing stable malaria with seasonal variations.  The remaining 60% of endemic 




responsible for 96% of malaria cases, while P. malariae and P. ovale are responsible for 
the rest (President's Malaria Initiative, 2018).  
2.3 The Vector 
The Malaria parasites that exclusively cause disease to humans are transmitted by 
approximately 40 mosquito species of the Anopheles genus (Bhatt et al., 2015). The most 
prevalent in Africa include, Anopheles funestus, Anopheles gambiae sensu stricto and 
Anopheles arabiensis (Sinka et al., 2010). Males of Anopheles spp transfer 20-
hydroxyecdysone; a steroid hormone, to the females during mating. Availability of the 
hormone has been related to favourable conditions for development of Plasmodium spp 
(Mitchell et al., 2015). 20‑hydroxyecdysone (20 E) induces a cascade of events that prevent 
further copulation of A. gambiae females, while increasing egg production and hence egg 
laying (Mitchell et al., 2015). Since egg production involves blood feeding, the parasite takes 
advantage of the reproductive needs of the mosquito to achieve its own transmission between 
vertebrate hosts. The high rate of reproduction seen in A. gambiae is a major factor for their 
ability to transmit high levels of Malaria. After each blood meal, it is assumed that the female 
mosquito  species can lay over one hundred eggs and fertilize them  with sperm obtained 
from a single mating (Baldini et al., 2012).  
2.4 Plasmodium Parasite 
Plasmodium spp. are single-celled eukaryotic organisms of the phylum Apicomplexa (Florens 
et al., 2002). Among the five species of parasites responsible for human malaria, P. 
falciparum is attributed to majority of diseases and deaths in Africa (Gething et al., 2016). 
Moreover, P. falciparum results in severe malaria, complications during  pregnancy and an 
estimated daily mortality of one thousand two hundred African children aged 5 and below 
(Maitland, 2016). On the other hand, P. vivax is predominant in tropical and temperate 
regions for example Asia and Ethiopia and is implicated for Malaria sicknesses and deaths in 
Central and South America. This can be explained by the species’ ability to survive in 
unfavourable climatic regions and majorly its ability to exist dormant as hypnozoites in the 
human liver for many days or even years. The process of Malaria infection is facilitated by a 
natural surface protein of erythrocytes called Duffy antigen for which many Africans are 




(Miller et al., 1976). Plasmodium ovale and Plasmodium malariae are  also endemic in 
Africa and Asia, but are specifically adverse in West Africa (Sutherland et al., 2010). 
Plasmodium knowlesi previously thought to cause disease to non-human primates has been 
reported to only cause disease to humans but can also lead to severe complications and even 
death (Cox-Singh et al., 2008). 
2.4.1 The Life-Cycle of Plasmodium Species 
The Plasmodium parasite develops in two cycles which take place in its two hosts (mosquitos 
and primates) (Noland et al., 2003). During a blood meal, sporozoites (approximately 100) 
are transferred from the salivary duct of the mosquito to into the venules of the host (Collins 
& Jeffery, 2007). After 30–60 minutes, the sporozoites are transported by blood into the liver 
and initiate the hepatic cycle where they invade hepatocytes. The sporozoites develop into 
schizonts consisting of many hepatic merozoites. The merozoites are then released for 
systemic circulation hence launching the erythrocytic cycle. This cycle represents the asexual 
stage of reproduction, and it is at this stage that the symptoms of Malaria are manifested, 
mostly 4-8 days after initiation (Karunaweera et al., 1992). While in the RBCs, the 
merozoites develop within 36–72 hours between invasion to haemolysis. Thus, with a single 
bite, episodes of  fever happen every 36–72 hours, during which time the infected RBCs lyse 
and release endotoxins in great mass (Wijesekera et al., 1996). While the merozoites continue 
their replication within the RBCs, some differentiate into gametocytes. However, P. vivax 
and P. ovale have a somewhat unique cycle in its primate hosts where some hepatocellular 
sporozoites, remain in uninucleate form, called hypnozoites. These hypnozites resume 
hepatic development facilitated by factors that remain unknown, causing malaria relapses in 
varied periods after initial exposure (Galinski et al., 2013). Released Merozoites further 
invade other RBCs , and sometimes they segregate into male or female gametocytes (Baker, 
2010) . The gametocytes are then sequestered in the capillaries of the skin from where they 
are picked by the mosquito in the subsequent bites. The male gametocytes undergo mitosis in 
the gut of the mosquito producing microgametes; while the female gametocyte grows into a 
macrogamete and fuses with the motile male microgametes forming a diploid zygote. The 
zygote grows into an ookinete; which leaves the lumen of the gut a as an oocyst. The 
sporozoites are formed from the oocysts after several series of reproduction, afterwhich they 
relocate to the salivary glands of the mosquito. The female mosquito may therefore be 




(Annan et al., 2007). Antimalarial drugs exert their pharmacological action at varied critical 
stages of the parasites’ cycle. Drugs that inhibit plasmodial invasion of  hepatocytes possess 
prophylactic effects, while those that prevent erythrocytic stage have curative effects during 
the symptomatic stage of the disease, The transmission-blocking agents prevent the formation 
or production of gametocytes in the invertebrate host (including those that kill blood-fed 
mosquitoes) (Saifi, 2013 & Phillips et al., 2017). The parasite's reproductive cycle and drug 
action sites are as summarised in Fig. 1.  
 
Figure 1: The lifecycle of Plasmodium Parasite highlighting areas of antimalarial drug 
action (Adopted from Phillips et al., 2017 )  
2.5 Parasite Invasion and Replication 
Plasmodium spp's red blood cell stage marks the symptomatic stage of malaria infection, 
since erythrocytes are the sites of parasite replication. The parasites enter the red blood cells 
by precise ligand-receptor association modulated by parasite surface proteins that interact on 
the host erythrocyte or reticulocyte (Paul et al., 2016). Plasmodium falciparum may infect 
and reproduce in the RBCs and reticulocytes, while P. vivax and other species attack 
reticulocytes which are always less than erythrocytes (Lim et al., 2016). Once in the RBCs, 
hundreds of proteins are shuttled cell cytoplasm of the host cells and cell surface by parasites 




pathogenesis (Mercier et al., 2005). The parasites’ rapid replication may hit > 1012 parasites 
per patient during symptomatic stage of the disease. This proliferation needs sustained 
nucleotide molecules for DNA and RNA synthesis, and as such, most antimalarials target the 
biosynthesis of pyrimidine (Phillips et al., 2017).  
2.6 Pathogenesis 
Severe malaria is multifactorial in nature with parasite and host factors contributing to the 
seriousness of the disease (Miller et al., 2013). The infected RBCs which release endotoxins 
and the parasites (a combination of haemozoin and parasite DNA) highlight plasmodium 
species’ pathogenic mechanisms. This phenomenon triggers increase in Toll-like receptor 9 
(TLR9), which modulates the immune system of the hosts against the disease causing agents 
(Parroche et al., 2007). The upsurge in TLR9 results in escalation of tumour necrosis factor 
(TNF) and eventual symptoms of malaria, especially fever (Vijaykumar et al., 2001). 
Furthermore, the membrane of infected red blood cells often stiffens, leading to capillary 
obstruction and this is life-threatening in patients with acute malaria (Parroche et al., 2007). 
The pathogenesis of malaria is aided by surface proteins specific to the parasite. In P. 
falciparum, a large surface antigen encoded by the var gene family comprising of 
approximately 60 genetically classified members of three subgroups A, B and C. The B and 
C subtypes interfere with the cells of the host  through CD36 (a platelet glycoprotein 4), 
while the  subtype A interferes with non-CD36 binding associations responsible for extreme 
cases of malaria, like cerebral malaria (Smith, 2014; Duraisingh & Horn 2016; Wassmer et 
al., 2015). The endothelial vasculature cytoadherence of infected RBCs is mediated by P. 
falciparum erythrocyte membrane protein 1 (PfEMP1) encoding var genes. Subgroups B and 
C account for more than 80% of the variants of PfEMP1. In addition, group A variants of 
PfEMP1 promote the binding of infected red blood cells to the endothelial protein C receptor 
(EPCR) and the intracellular adhesion molecule 1 (ICAM) of cerebral malaria, hence the 
pathological characteristics of cerebral malaria (Gillrie et al., 2016). Evidence of positive 
selection of people residing in endemic areas with heterozygous genotypes for haemoglobin-
encoding alleles are naturally protected from malaria infection. Nevertheless, with cases of 
homozygous genotypes, these alleles cause serious disorders of the blood  such as 
thalassaemia and sickle cell disease (López et al., 2010; Elguero et al., 2015). Invasion of red 
blood cells by P. vivax parasite is modulated by Duffy antigen (a red blood cell-surface 




antigens have been linked to reduced spread of P. vivax caused malaria among people of 
African origin (Cheng et al., 2016).  
2.7 Mainstay Control Measures 
In sub-Saharan Africa, the cornerstones of malaria control are long-lasting insecticide nets 
and indoor insecticide spraying. Together with effective treatment, these approaches are 
estimated to have decreased malaria morbidity and mortality worldwide by 41% and 62% 
between 2000 and 2015 (Protopopoff et al., 2018; Killeen & Ranson, 2018). Today's most 
popular and successful vector control techniques the use of insecticide-treated, long-lasting 
and wash-proof networks. The fibre of these networks is impregnated with an insecticide that 
retains its effectiveness after up to 20 lab washes, with 3 years of approved use (Chanda et 
al., 2014). The biological and behavioural diversity of mosquitoes, however, complicates the 
use of these vector control methods. For example, net treated with insecticides alone is 
unlikely to be sufficient due to residual malaria transmission (Parker et al., 2015). This leaves 
chemotherapy as the most reliable alternative to clear residual plasmodium parasites. There 
are several pharmacological options available for malaria treatment: chloroquine, quinine, 
primaquine, mefloquine, pyremethamine, derivatives of artemisinine such as artemether and 
artesunate and amino alcohols such as Halofantrine and Lumefantrine (Bahekar & Kale, 
2013). Their respective compounds are as shown in Fig. 2. Uncomplicated Malaria is 
currently managed by Artemisinin-based combination treatments (ACTs) because of their 
effectiveness. The drug molecules partnered with artemisinin derivative determines the 
efficacy of the combination. For example, Artemether,-lumefantrine, artesunate, mefloquine, 
and dihydroartemisinine, piperaquine, typically exceed 95%. The use of artemisinin 
derivatives is a serious concern during the first trimester of pregnancy where they should not 
be used unless viable options exist (Nosten & White, 2007). As with other infectious 
diseases, the principle behind combination chemotherapy in malaria is that when two drugs 
are used with different modes of action and different mechanisms of resistance are 
established, then the per-parasite probability of creating resistance to both drugs in the same 
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Figure 2: Artemisinin Pharmacophore (1) and its Derivatives, Artesunate (2) and 
Dihydroartemisisnin (3) 
2.8 Antimalarial Drug Resistance 
Resistance to most drugs has not only been implicated in enhanced mortality, but it is also an 
economic burden in the fight against malaria (Bloland, 2001). The resistance of P. falciparum 
to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) prompted introduction of ACT 
that has now been adopted by most countries for treatment of malaria (Ishengoma et al., 
2015). Consequently, the use of Chloroquine as the main option to treat malaria has been 
discontinued in some countries in Africa, for example Kenya (Gathirwa et al., 2008). Recent 
reports indicate fears of rising cases of decline in efficacy of ACT and artesunate 
monotherapy, as stated in a case study done in western Cambodia (Alker et al., 2007; Denis 
et al., 2006; Noedl et al., 2008). These isolates are highly likely to spread to other areas 
endemic to malaria, including sub-Saharan countries, as was the case with the past drugs for 




propagated by mutations in the propeller region, the Kelch 13 (K13), hence delayed clearance 
of the parasite both in vitro and in vivo (WHO status report). Approximately one hundred and 
eighty six K-13 alleles including one hundred and eight mutations that are not synonymous 
have been identified. There are rare, but very diverse, non-synonymous mutations in Africa. 
These mutations have been reported in Chad, Cameroon, Gabon, Comoros, Kenya, Gambia, 
Madagascar, Mali, Malawi, Togo, Uganda and Zambia (WHO, 2015). Given these rising 
cases of P. falciparum resistance to conventional drugs, there is need to develop alternative 
control measures for management of malaria. For decades now, medicinal plants have been 
used to treat pain without resistance development. However, research to isolate bioactive 
compounds from plants that have shown promising antimalarial activity needs to be done. 
2.9 Antimalarial Drug Discovery and Associated Challenges 
The WHO and the Bill and Melinda Gates Foundation announced almost a decade ago the 
long-term goal of malaria eradication. This ambitious plan has had profound achievements 
attributed to the use of existing therapy compared to the situation at the start of the 
Millennium (Burrows et al., 2017). As such, efforts have been channelled to drug discovery 
research from natural products. However, the results are yet to bear substantial impact. Of the 
more than 1300 new drugs developed between 1975 and 1999 for all diseases, only 13 were 
for tropical diseases. Just about 0.1% of global health research funding was dedicated to the 
development of drugs for tuberculosis and identified tropical pathologies (malaria, 
trypanosomiasis and leishmaniosis), which together accounted for an estimated 5% of the 
global disease burden in the year 2000 (Pink et al., 2005). If the fight against malaria is to be 
won, novel drugs are urgently needed. Sadly, the standard drug discovery pathways have 
produced few medicines to treat emerging diseases affecting developing countries. Despite 
this concern, there is hope for retrench. First, the successful genome sequencing of P. 
falciparum presents enormous potential drug targets and the current advances in malaria 
genetics provide robust techniques of determining potential targets. The discovery and 
development of new and affordable drugs may be realised with the critical role played by 
pharmaceutical companies (Fidock et al., 2004). Natural products remain a promising source 
of conventional medicines, thus increasing interest in research in the field (Harvey et al., 
2015). Since natural products are formed by proteins to interact with proteins, they can 
therefore be considered by definition as scaffolds (Balamurugan et al., 2005). The United 




2010 were either obtained from natural products or are derivatives there from (Newman & 
Cragg, 2012). Additionally, a recent report from Novartis suggests that while conducting 
high-throughput screening, natural products is a source of compounds with unfathomable 
diversity compared to synthetic and combinatorial molecules, hence a higher hit rate (Bender 
et al., 2009). In light of great interest and potential vested on natural products as sources of 
new antimalarial drugs, there remain substantial challenges to be overcome. The United 
Nations Convention on Biological Diversity mandated to oversee global access to natural 
products, and claims of inability of natural products to match the drug discovery approaches 
of molecular targets have been raised. Furthermore, the challenges of repeated isolation of 
non-novel compounds and the complexity of processing natural products in pharmaceutical 
manufacturing have significantly curtailed the progress of antimalarial drug development 
from natural products. Finally, the yet to be fulfilled supposition that combinatorial chemistry 
will avail all the required chemicals for successful discovery of leads has dragged the once 
great promise of natural products as sources of novel medicines (Newman & Cragg, 2012).  
2.10 Lippia Kituiensis Vatke 
The genus Lippia of the family Verbenaceae consists of flowering plants known for their 
aromaticity based on their high contents of essential oils (Arthur et al., 2011). This genus of 
plants grows in most parts of Countries in South and Central America and parts in Tropical 
Africa (Nara et al., 2016 ). Lippia kituensis has been shown to possess mosquito repellent 
properties (Kosgei et al., 2014). Extensive research has been done on plants of this genus. 
Leaves of L. graveolens are used for culinary purposes (Tucker et al., 2009). In other studies, 
Magano et al. (2011) reported that ccamphor oil from L. kituiensis possessed a significant 
repellence against maize weevils compared with NN-diethyltoluamide (DEET) Other 
ethnobotanical uses of genus Lippia include management of malaria, gastrointestinal and 
respiratory problems apart from possessing, antispasmolitic, hypotensive, sedative and anti-
inflammatory activities (Jigam et al., 2009). Other plants in the family of Verbenaceae 
including Lippia javanica have been used to treat fever, colds, cough, malaria, wounds, chest 
pains, diarrhoea, asthma, bronchitis, cancer, anti-amoebic, antidiabetic, antimicrobial, 
antioxidant, antiplasmodial and pesticidal effects (Alfred, 2017). Although plants of the same 
species (Lippia) have shown efficacy against Malaria (Gasquet et al., 1993), it is worth 
noting that claims of antimalarial activity of L. kituensis have not been validated 





MATERIALS AND METHODS 
3.1 Reagents and Chemicals 
Silica gel powder (70-230 mesh), pre-coated Thin Layer Chromatography Plates, solvents 
(Hexane, Ethyl Acetate, Dichloromethane and Methanol) and biological reagents and 
consumables were purchased from sigma Aldrich. Chloroquine diphosphate and radiolabelled 
Hypoxanthine Monohydrate salt were generously donated by Dr. Jeremiah Gathirwa of 
Kenya Medical Research Institute.  
3.1.1 Ethical Statement 
The KEMRI in-house approval bodies namely, the Scientific and Ethics Review Unit 
(SERU), and the Animal Care and Use Committee (ACUC) approved the study under 






























Figure 3: Hypothetical Outlook of the Study 
 
3.2 Extraction of the Processed Plant Material 
Organic extraction was done with brief modifications of the method described by Gathirwa et 
al. (2008). Briefly, a top pan balance (Slater model-323, China), was used to weigh 1 
kilogram of plant powder into a 5-litre flat-bottomed flask. Methanol (MeOH) and 
Dichloromethane (DCM) mixture in the ratio 1:1 was used to macerate the plant material. 
The powdered product was extracted at room temperature for 24 hours, which was repeated 
twice. The material was filtered using the whatman filter paper and concentrated using a 
rotary evaporator at reduced pressure (BUCHI Rotavapor model No. R-114; Switzerland) 




3.3 Thin Layer Chromatography 
A small portion of the total extract of L. kituiensis was reconstituted in MeOH: 
Dichloromethane mixture and spotted on cut pieces of pre-coated Thin layer chromatography 
plates (TLC). The plates were then developed in different solvent pairs (Sule et al., 2011). 
Upon development, assessment of plates was done by observation on open light, under UV 
(254 nm and 365 nm), and after vanillin spray with plates heated to 110oC for 5 minutes. 
Based on retention factors (Rf) obtained from developed plates, the best solvent mixture to 
run a column was identified. Hexane and Ethyl acetate mixed in the ratio 4:1 gave the best 
separations and hence the pair was established as ideal mobile phase in liquid column 
chromatography. 
3.4 Column Chromatography 
The open column chromatography technique was adopted to separate the total extract where 
briefly, a glass column of diameter 10 centimetres was packed with a slurry of 300 g of Silica 
powder (70-230 mesh, using 100 % Hexane) (Walker et al., 2015). The slurry was 
immediately transferred into the column with intermittent swirling to prevent solidification. 
The wetness of the gel was maintained by several elutions of 100% hexane. After 24 hours of 
undisturbed packing, Hexane was drained and 60 g of the total extract of L. kituiensis was 
mixed with 70 grams of silica and 100% hexane. The mixture was swirled to homogeneity 
and transferred into the packed column. Hexane (500 ml) was then loaded into the column to 
begin fractionation as fractions were collected in different flasks. The polarity of the mobile 
phase was progressively increased until no further separations could be identified as guided 
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Figure 4: Liquid chromatography showing progressive development of fractions (1, 2 







Figure 5: Fractions after column chromatography and fractions after combination as 
guided by TLC plates 
 
3.5 Drug Preparation for Bioassays 
For in-vitro antiplasmodial assays, stock formulations of the fractions were constituted at 
concentrations 1 mg/ml in DMSO diluted by RPM1640 to attain a final 0.2 % content of 
DMSO. Based on in vitro cytotoxicity results, where fractions exhibited moderate to low 
toxicity, and guided by Mzena et al. (2018), two dosages (500 mg/kg and 1000 mg/kg) were 
chosen for in vivo assay. Dosages for in-vivo assay were prepared in a vehicle composed of 
10% Tween 80, 3% DMSO and PBS (Basir et al., 2012). Calculation for dosages preparation 
were as illustrated below. The vehicle served as the negative control in each case 




3.5.1 In vivo Drug Preparation Per Dogase-1000 mg/kg of Body Weight  
1000 mg   1000 g 
?  20 g 
= (20/1000) ×1000 mg 
= 20 mg per mouse 
Therefore, a four-day dose for 5 animals per group, 
= 20 mg×5 animals ×4 days 
400 mg of drug was weighed into centrifuge tubes 
3.5.2 Drug Dissolution 
Each animal was to receive an oral 0.2 ml of drug solution 
Therefore, 0.2 × 5 animals per group= 1 ml 
Since they were organic extracts, they were dissolved in 3% DMSO and topped up to 1ml 
using 10% Tween 80 and PBS 
3.6 In vitro Screening of Fractions for Antiplasmodial Activity 
Antiplasmodial activity of fractions was done through a semi-automated technique on two 
culture-adapted strains of P. falciparum namely, chloroquine sensitive (D6) and chloroquine 
resistant (W2) as earlier described by Desjardins et al. (1979). Briefly, culture media 
consisted of RPMI 1640, 25 MM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES )at pH 7.4, supplemented with 12.5% human serum (obtained from pooled blood 
types A, AB and O and inactivated by heating). Haematocrit was prepared at 6 % human 
erythrocytes obtained from donors of blood group O+  making 5 ml total volume in culture. 
Cultures were kept in sealed flasks at 37°C, and gassed by gas mixed as 92% N2 , 3% O2 and 
5% CO2. Fractions were prepared at 100 mg/ml by DMSO whose concentration was diluted 
by RPM1640 to attain a final 0.2% content of DMSO. Test samples were constituted in 
DMSO (diluted to < 0.2% DMSO content) while Chloroquine was disolved in distilled water. 
The wells of the sterile, flat-bottomed 96-well plates were filled with 25 µl of screening 
medium (Corning Incorported, Costar®, U.S.A). Constituted test samples (50 µl) at starting 
concentration of 100 µg/ml was seeded to wells of row B in duplicate. After proper mixing, 
25 µl of drug solution at row B was transferred to wells at row C successively to row H 200 




excluding wells A9 to A12, where 200 µl of healthy erythrocytes at 1.5% hematocrit) were 
seeded and taken to be the negative controls. Plates were then incubated for 48 hours at 37 0C 
in a chamber of mixed gas ( 92% N2, 3% O2 and 5% CO2) at 95% humidity. The radiolabel 
(hypoxanthine-25 µl ) was then seeded into the plates at 0.5 µlCi in every well. The plates 
were further incubated for 18 hours after which they were frozen to negative 20 °C. The 
plates were then thawed and the  contents transferred onto filter mats (A 1450-421; Perkin 
Elmer) by use of a cell harvester (Wallac Perkin Elmer; 1295-004 Betaplate). The filter mats 
were then oven-dried and saturated in 10 ml scintillation fluid (Perkin Elmer, Beta Scintilla®; 
Schwerzenbach, CH) while covered in special foil (1450-432; Perkin Elmer). A Betaplate 
scintillation counter (Wallac Perkin Elmer, Betaplate) was then used to determine icorported 
hypoxanthine [3H] yielding results as counts per minute (cpm). The results of each well were 
reported as counts per minute and recorded as a percentage of untreated (positive) control 
(wells from A1 to A8; no test compound). The background effect was substracted from the 
reading of the negative control. Linear interpolation was important in calculation of IC50s 
(concentration of the drug at which 50% of radiolabelled hypoxanthin was inhibited relative 
untreated controls). 
3.7 Cell Culture and Cytotoxicity Assay 
A calorimetric-based assay that uses 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) dye, which measures conversion of MTT into formazan crystals by living 
cells, hence determining mitochondrial activity was used to asses cytotoxic levels of fractions 
as earlier described by Kaur et al. (2018). Vero (E6) cell line was cultured in supplimented 
Dulbecco’s Eagle’s media supplemented with 10% heat inactivated Fetal bovine serum 
(Himedia), l-Glutamine and treated with penicillin/streptomycin (100 µgml−1), gentamycin 
(100 μgml−1). Culture flasks were incubated in a CO2 incubator (90 % Relative Humidity 
and 5% CO2) at 37 °C. Upon attainment of maximum confluence (90-100 %) viewed under 
an inverted microscope (Fig 6), the cell monolayer was trypsinized and seeded at 2 × 105 
cells/ml in each well of the 96 well plates and incubated for 24 hours. Drug concentrations 
were prepared (1000 μg/ml), seeded at the highest concentration and serial diluted to afford 
different concentrations across the plate. Plates were then re-incubated for fourty eight hours. 
Thereafter, 10 µl of MTT solution (5 mgml−1) was then added into all wells and incubated 
for 4 hours. The plates were emptied of media and the formazan crystals formed were treated 




(Thermofisher, MultiscanGo Spectrophotometer), absorbances of each well were determined. 
Dose response curves was plotted from inhibition data  and used to determine CC50 values 
(concentration required to inhibit/alter 50% of the cells). Selectivity index (SI=IC50/CC50)  
which measures the significance of drugs by comparing their toxic levels and their 
discriminatory inhibitory effect on P. falciparum was determined (Wright & Phillipson, 
1990). 
 
Figure 6: Morphological appearance of Vero E6 cell line at almost 100% confluence 
(Magnification ×400) 
3.8 In-vivo Antimalarial Assays 
Dosages for the in vivo assay were prepared in a vehicle composed of 10% Tween 80, 3% 
DMSO and PBS. The vehicle served as the negative control in each case respectively. We 
adopted a model involving the use of  Plasmodium berghei NK65 strain to study in vivo 
antimalarial activity on Swiss albino mice according to Peter’s suppressive test (Peters, 
1975). Upon attainment of ethical approvals, Naïve Swiss albino mice weighing 20±2g were 
acclimatized for 48 hours. Frozen stabilates of P. berghei were thawed and injected into a 
group of 3 animals for propagation. Assessment of parasite growth was done microscopically 
and upon attainment of approximately 20% parasitaemia, blood was drawn from the passage 
mice (parasite donors) by cardiac puncture and reconstituted to 2% in phosphate saline 
glucose. Each of the 40 mice were injected in the peritoneal cavity with 0.2 ml of blood 
(infected) at an estimated 2x107   P. berghei on day 0. Animals were then randomized into 
cages of 5 each i.e.; positive control (chloroquine 10mg/kg), negative control and the 6 
fraction-test groups which received 1000 mg/kg and 500 mg/kg of test groups. All cages were 




rodent pellets. A 22-gauge cannula (Harvard Apparatus; length = 25.4 mm, ball diameter = 
1.25 mm) was used for oral administration of drugs 2 hours after infection. This continued on 
days 1 to 3 (24, 48 and 72 hrs. Drug administration was stopped after 96 hours since 
infection. On day 4, microscopic slides were made by drawing blood through the tail veins. 
Slides were fixed in methanol and stained using 10% Giemsa for 15 minutes. Parasitemia in 
each group was assessed microscopically under high magnification and oil immersion. 
Percentage chemosuppression of fractions was calculated with mean parasitemia on day 4 as 
described by Tona et al. (2001). Raw data on parasitemia and chemosuppression per 






Figure 7: Microscopic appearance of heavily parasitized RBCs (arrows illustrate 
parasitized RBCs). Slide prepared from blood obtained from a donor 
mouse. Magnification (×1600) under oil immersion 
3.9 Preliminary Qualitative Phytochemical Screening 
Phytochemicals refers to a group of compounds found in plants which have found 
applications in various aspects of human life, particularly phmaceutical uses (Igwe, 2015). 
Assessment of secondary metabolites in the fractions was done using standard procedures and 
tests as cited. Availability or absence of alkaloids, tannins, saponins, phenols and glycosides 
was analysed and qualitatively indicated as (+) when present and (-) when absent. Fractions 
were constituted in their respective solvent mixtures of fractionation prior to each 
phytochemical test. 
3.9.1 Alkaloids 
The constituted fractions (5 ml each) was added to tubes of  2 ml dilute Ammonia and 5 ml of 
Chloroform added. 1 ml of acetic acid was then added and separated into two portions based 




solution was added while Mayer’s reagent was added to the other. The appearance of a cream 
color on the portion in Mayer’s reagent and a brown precipitate in the Draggendorff’s reagent 
confnirmed presence of alkaloids (Radhia et al., 2018). 
3.9.2 Phenols 
Phenols are a group of compounds that possess hydroxyl groups attached to an aromatic ring. 
They are the most abundant compounds in the plant kingdom (Lattanzio, 2013). To 2 ml of 
each fraction, 5% aqueous ferric chloride (2 ml) was added. Appearance of blue colour 
confirmed for phenols content (Ayoola et al., 2008). 
3.9.3 Saponins 
Aliquots of each fraction at 5.0 ml was diluted in 20 ml of deionized water, shaken 
vigorously and observed. Persistent foaming indicated the presence of saponins (Nkwocha, 
2015). 
3.9.4 Terpenoids 
To 5 ml of each fraction, 2.0 ml of chloroform was added and boiled with 3 ml concentrated  
sulfuric acid. Formation of grey colour showed availability of terpenoids (Ukoha et al., 
2011). 
3.9.5 Tannins 
Ferric chloride (0.1 %) of volume 1 ml was dispensed in drops to tubes containing 3 ml of 
each fractions and observed for blue-black colouration (gallic tannins) or blue-green 
(cathechic tannins) (Bargah, 2015). 
3.9.6 Glycosides 
A volume of 1 ml concentrated sulphuric acid was poured on walls of an inclined tube 
containing 1ml each of the fractions separately. Ten percent of Ferric chloride solution was 
added in drop wise and a brown ring was observed indicating presence of glycosides 




3.10 Fourier Trans-Infrared Spectroscopy 
Fraction Lk-3 (dark yellow paste) exhibited outstanding antimalarial efficacy against 
Plasmodium berghei at an oral dose of 1000 mg/kg. A sample from this fraction was 
therefore subjected to FTIR at Jommo Kenyatta University of Agriculture, Science and 
Technology (JKUAT). The Shimadzu FTIR spectrophotometer (FTS- 8000, Japan) was used 
to analyse the functional groups as  described  by Memon et al. (2015). The standard KBr 
disc method was used, where briefly, crystal sample was ground with KBr in the ratio 1 to 10 
milligrams respectively. The mixture was pressed into a pellet using a hydraulic press and 
scanned with a spectral resolution set at 4 cm–1 and the scanning ranged from 400 to 4000 
cm–1. 
3.11 Gas Chromatography-Mass Spectroscopy Analysis  
Gass chromatography couled to a mass spec housed  at JKUAT was used to further determine 
compounds in fraction Lk-3. This was done as previously described by Igwe (2015). A 
Shimadzu QP 2010-SE GC-MS coupled to an auto sampler was used for analysis. Ultrapure 
Helium was used as the carrier gas at a flow rate of 1 ml per minute. A BPX5 (non-polar 
column, 30 m; 0.25 mm ID; 0.25 µm film thickness, composed of 100 % Dimethyl poly 
siloxane) was used for separation. The GC was programmed as follows: 50 ˚C (1 minute); 5 
˚C /min to 250˚ C (1 minute). Total runtime was 42 minutes. Injection temperature was set to 
2000 C, while the interface temperature was set at 2500C. The electron impact ion source was 
set at 2000 C and mass analysis was done in full scan mode, 50-550 a.m.u. The compounds 
were then identified from the GC-MS peaks upon compariosn with the National Institute of 







RESULTS AND DISCUSSION 
4.1 Results 
4.1.1 Thin Layer Chromatographic Analysis of Total Organic Extracts of Lippia 
kituiensis 
A total of 32 fractions were obtained and concentrated as described previously. Thin layer 
Chromatography (TLC) profile was used to determine fractions that contained similar 
compounds, based on their retention factors. Such fractions were pooled to make single 
entities. The TLC plate was run in a mobile system consisting of Hexane and Ethyl acetate in 
the ratio 8:2. Eventually, 6 fractions were obtained as summarised in Table 1. When observed 
under UV 254 nm, fractions Lk-4 and largely Lk-5 contained fluorescent spots, Fig 6.  
 
Figure 8: TLC plates when observed under 254 nm UV and appearance after Vanillin 
spray 














Lk-1 3 3.483 3.97 Dark green gum 
Lk-2 6 5.072 5.78 Dark green gum 
Lk-3 3 2.051 2.34 Dark Yellow paste 
Lk-4 4 3.603 4.10 Dark green paste 
Lk-5 5 3.347 3.81 Dark green paste 






4.2 Antiplasmodial Activity of Fractions of L. kituiensis and their Cytotoxicity 
Preliminary in-vitro antiplasmodial assay was performed on P. falciparum strains of W2 
(chloroquine-resistant) and D6 (chloroquine-sensitive). The positive control was chloroquine 
diphosphate, while the negative control was DMSO. In vitro antiplasmodial activity of 
fractions is shown in Table 2. 
Table 2: Antiplasmodial Activity of Fractions against W2 and D6 Plasmodium strains 
Fraction 
IC50 of Anti-plasmodial Assay (M±SD) 
W2  (µg/ml) D6  (µg/ml) 
Lk-1 >100 79.41±16.61 
Lk-2 68.42±5.55 78.85±5.82 
Lk-3 45.16±9.05 30.43±0.68 
Lk-4 24.18±2.50 30.82±18.01 
Lk-5 24.42±5.95 19.45±6.20 
Lk-6 56.75±5.12 36.53±14.42 
Cq 77.86±4.09 ng/ml 15.71±6.49 ng/ml 




Figure 9: Graphical representation of Antiplasmodial Activity (IC50 values) of Fractions 
against W2 and D6 Strains of Plasmodium 
The fractions displayed medium to low activity; where efficacy was graded as IC50 μg / ml 




2018). Generally, fraction LK-5 showed the highest antiplasmodial activity against 
chloroquine-sensitive strain (D6) with IC50 of 19.45 µg/ml and second highest activity against 
chloroquine-resistant strain (W2) IC50 24.42 µg/ml respectively. Notably, efficacy increased 
with increasing polarity of the mobile phase except in fraction Lk-6. Judgement of cytotoxic 
levels was made where a fraction was considered highly toxic when CC50< 10 μg/ml, 
moderately cytotoxic with CC50 ranging from 11–30 μg/ml, slightly cytotoxic when CC50, 
31–50 μg/ml, and preferably non-toxic with CC50> 50 μg/ml (Berthi et al., 2018). Hence, all 
fractions were found to be potentially non-toxic, showing CC50 values >50, except Lk-4 
(46.26 μg/ml). Selectivity indices (SI) were calculated as previously explained by Rocha et 
al. (2012). The fractions generally depicted lower selectivity indices against D6 compared to 
W2 plasmodium strains. However, with SI > 2 against both parasite strains, Lk-5, which also 
exerted the best antiplasmodial efficacy showed specific activity rather than toxicity. 
Table 3: Cytotoxicity and Selectivity indices of fractions 
Fraction 
CC50 (µg/ml) against Selectivity Indices of Fractions 
Vero E6 Cell  line W2 D6 
Lk-1 71.21   0.71 0.89 
Lk-2 55.00    0.80 0.69 
Lk-3 64.90 1.44 2.13 
Lk-4 46.26 1.91 1.50 
Lk-5 67.13 2.75 3.45 
Lk-6 69.96 1.23 1.92 
Cq n/d n/d n/d 
CC50- Drug concentration that reduces cell viability (Vero E6 cell line) by 50%. Selectivity 
index- Ratio of IC50 to CC50-measure of drug’s ability to target parasite, Cq: Chloroquine 
n/d: not done. 
4.3 Antimalarial Activity of Fractions of L. kituiensis 
Two dosages of each fraction (500 mg/kg and 1000 mg/kg) were screened in a mouse model 
following Peter’s suppressive test (Peters, 1975) (results are as shown in Table 4). Drug 
dosages were administered orally. Chloroquine (10 mg/kg) was used as the positive control, 
while the vehicle served as negative control. Chemo-suppression was used as a measure of 




Table 4: In vivo antimalarial activity of fractions of L. kituiensis against P. berghei 
(Anka 65) 
Fractions 
Parasite density per dose  
(Mean±SD) 
 Chemo-suppression per dose 
(Mean±SD) 
500 mg/kg 1000 mg/kg 500 mg/kg 1000 mg/kg 
Lk-1 2.30±0.43 3.99±0.07  78.64±4.01b 73.04±044b 
Lk-2 5.47±0.65 4.10±0.52 49.24±6.06b 72.27±3.51b 
Lk-3 3.99±0.82 2.96±0.16 62.24±7.61b 80.01±1.07b 
Lk-4 5.33±0.44 4.39±0.55 50.57±4.16b 70.35±3.72b 
Lk-5 4.14±0.42 4.01±0.89 61.59±3.95b 72.91±6.06b 
Lk-6 5.74±0.59 4.09±0.55 46.77±5.51b 72.37±3.71b 
Cq -(10 
mg/kg) 
0.56±0.37 1.10±0.31  94.72±3.43a 92.57±2.11a 
Placebo 10.78±0.70 14.82±0.90 0.00b 0.00b 
Cq-Chloroquine-was the positive control administered at 10mg/kg, Placebo-Negative 
control- (vehicle), Parasite density-Denotes percentage of infected erythrocytes, a, b P≤ 0.05 
level of significant difference between groups against positive control and negative control 




Figure 10: Chemosuppression of fractions against P. berghei at 500 mg/kg and 1000 
mg/kg 
 
Generally, all fractions exhibited significant antimalarial activity when compared to the 
negative control. Their efficacy was however insignificant on comparison with the positive 
control. A dose dependent activity was observed with the highest efficacy seen in animals 
treated with 1000 mg/kg. However, 500 mg/kg of Lk-1 was more efficacious than it was at 
1000 mg/kg. This scenario can be linked to toxicity since mortality was seen day 2 post-




Fraction Lk-3 was found to possess the most pronounced efficacy during in vivo testing with 
percentage chemosuppression of 80.01 at 1000 mg/kg. This was consistent with in vitro data 
in Table 2, particularly against D6 strain. 
4.4 Qualitative Phytochemical Screening of L. kituiensis 
To determine classes of secondary metabolites in each fraction, qualitative phytochemical 
screening was conducted. Results are shown in Table 5. 
Table 5: Qualitative phytochemical screening of L. kituiensis  
+ = Presence - = Absence 
Comparatively, Lk-3 and Lk-5 demonstrated the richness of different secondary metabolites, 
hence the efficacy observed from the fractions. Notably, all the fractions except Lk-6 
indicated presence of alkaloids. These results are consistent with phytochemical screening of 
total extracts of L. kituiensis growing in Kenya, where alkaloids, Tannins and Glycosides 
were found (Omwenga et al., 2011).  
4.5 Spectral Patterns and their Interpretations for Fraction Lk-3 
Fourier transform-infrared spectral data complement the qualitative phytochemical screening 
of LK-3 depicted in Table 4. Presence of different classes of phytochemical species were 
obtained and suggestion of compounds given by gas chromatography coupled to mass 
spectrophotometer. Fourier transform-infrared results of Lk-3 are as indicated in Fig. 9 and 
Table 5, while compounds available in fraction Lk-3 are as indicated in Table 7. 
Fractions 
 Secondary Metabolites Screened 
Alkaloids Terpenoids Phenols Tannins Glycosides 
Lk-1 + - - - + 
Lk-2 + - - - + 
Lk-3 + + + - - 
Lk-4 + - - + + 
Lk-5 + - + - + 





Figure 11: Fourier transform-infrared Spectral pattern of Lk-3 
 
Table 6: Functional groups present in fraction Lk-3 
S/No Frequency range (cm-1) Functional Group identified 
1 3329.3-2657.7  O-H carboxylic acid 
2 1706.9  C=O saturated carbonyl group  
3 1465.8  C-H  methylene group from an alkane 
4 1591.2 and 1425.3  C=C stretching in aromatic ring 
5 1172.6, 1112.9, 1070.4 C-H weak bending in the aromatic ring 
6 1379.0 O-H bending due to Phenol 
7 974.0, and 723 Long chain Alkanes 
 
4.6 Compounds Present in Fraction Lk-3 Following Interpretations of GC-MS 
Spectra 
Eight compounds were identified where 3 have previously been reported for antimalarial 
activity and other pharmacological properties (structures are indicated below). 
Hexatriacontane (28.75%) was the major compound identified followed by Hentriacontane, 
3-methyl (7.13%) and Tetratetracontane (6.13%). The first compound to be eluted (retention 
time 6.758 minutes) needs further identification using nuclear magnetic resonance which was 
beyond the scope of the current study. Although the NIST library suggested 1, 3-Butanediol, 




Table 7: Compounds in Lk-3 identified by GC-MS 





Peak Area % 
1 6.758 Unidentified C8H14O4 174 0.99 
2 10.772 2,4-Di-tert-butylphenol  C14H22O 206 0.98 
3 13.417 2-Pentadecanone, 
6,10,14-trimethyl 
C18H36O 268 2.37 
4 14.02 Hexadecanoic acid, 
methyl ester  
C17H34O2 270 1.91 
5 14.33 l-(+)Ascorbic acid2,6 
dihexadecanoate 
C38H6808 652 5.88 
6 23.055 Tetratetracontane  C44H90 618 6.31 
7 26.435 Hentriacontane, 3-methyl C32H66 450 7.13 
8 21.594 Hexatriacontane   C36H74 506 28.75 
Three compounds identified have previously been reported to possess antimalarial activity 
and other pharmacological properties (structures and processes of their splitting are as shown 
below, while GC-MS chromatograms of all compounds are as indicated in Appendix 1) 
4.6.1 Hexadecanoic Acid, Methyl Ester (C17H34O2) 
The base peak at m/z 74 and m/z 87 were due to McLafferty rearrangement. Loss of a 
Methoxy group gave a peak at m/z 239 (C15H31O1
+). The peaks at m/z 115, 129, 143, 157, 
171, 185, 199, 213 and 227 follows fragmentation pattern of CnH2n-1O2













Figure 12: The 2, 4-Di-tert-butylphenol 
 
The molecular ion peak is m/z 206 corresponding to the formula C14H22O. The base peak at 
m/z 191 (C13H19O




peak at m/z 175 (C13H19
+). The loss of three methyl groups (1, 1-dimethylethyl) gave a peak 
at m/z 163 (C11H15O
+). The loss of water followed by 1, 2-propadiene gave peaks at m/z 147 
(C11H15
+) and C8H11
+ (Ethyl benzene) respectively. Similarly the peak m/z 107, C7H7O
+ (p-
cresol) was also due to loss of 2-butene from m/z 163. Peak at m/z 91 corresponds to 
C7H7
+ (hydroxyl tropylium ion) is as a result of benzylic cleavage. Other peaks noted at m/z 









Figure 13: Hentriacontane, 3-methyl 
 
The molecular ion peak is m/z 450 corresponding to the formula C32H66. The compound was 
identified as a hydrocarbon due to its fragmentation pattern. The mass spectrum of saturated 
hydrocarbons has a fragmentation pattern characterized by clusters of peaks and 




and C5 and the fragment abundances decrease smoothly. The base peak at m/z 57 was due to 
C4H9





4.7.1 Fractions of Total Organic Extracts of Lippia kituiensis 
The antimalarial activity of fractionated organic extracts of L. kituiensis and their cytotoxic 
levels have been revealed in this study. Moderate to low antiplasmodial activity was seen 
(Table 2). This can be linked to instability of the fractionated extracts which are normally 
protected by chlorophyll and/or other components in their native forms (Zani et al., 1997). 
The concerted antimalarial effects of the total extracts of L. kituiensis as depicted in previous 
reports by Mzena et al. (2017) could have also been compromised by the semi-purification 
process during fractionation  
4.7.2 Antimalarial Activity of the Fractions 
Outstanding efficacy observed during in vivo studies rather than in vitro suggests 
immunomodulatory activity of drugs which may be due to localization of specific 
phytochemicals including fatty acids such as linoleic acids, squalene and tannins which have 
previously been reported to possess immune-stimulating properties (Kumaradevan et al., 
2015;  Chakrabarti et al., 2012). These class of compounds (except Tannins) were found to be 
present in fraction Lk3 as illustrated by GC-MS data in Table 7.  
To the best of our understanding, this study reports for the first time the antimalarial potential 
of fractionated extracts of L. ktuiensis. Nevertheless, the genus Lippia has been assigned a 
number of pharmacological properties, including antimalarial, antimicrobial, antimicrobial, 
larvicidal, antispasmodic, analgesic, anti-inflammatory and antipyretic activities (Santos et 
al., 2016). Numerous studies on this genus have focused on their essential oils (Stashenko et 
al., 2013). The promising antimalarial activity observed is consistent with other reports on the 
use of plants in the same family for the management of Malaria. Among other 
pharmacological properties, Lippia javanica has been reported for use to cure fever or 
malaria (Maroyi, 2017). Ludere et al. (2013) isolated a compound (Lippialactone) with 




collected from Nigeria, Lippia multiflora was among plant samples from 11 families 
collected based on antimalarial ethnopharmacology (Ajaiyeoba et al., 2006). 
4.7.3 Qualitative Antimalarial Activity of Fractions of L. kituiensis 
Presence of secondary metabolites, especially alkaloids, phenolic compounds, and terpenoids 
could be responsible for the observed antimalarial activity. Although the particular study 
reports antimalarial efficacy of fractionated extracts of L. kituiensis (V) for the first time, 
reports of the medicinal value of the plant to the local communities have been reported 
previously. For example, Onyango (2013) reported lervicidal activity of extracts of L. 
kituiensis.  
4.7.4 Compounds Identification in LK-3 Using GC-MS 
Most of the compounds in fraction Lk-3 identified by GC-MS have been reported previously. 
Hexadecanoic acid, methyl ester  was earlier identified in whole plant extracts of Phyllanthus 
amarus a medicinal plant used to treat malaria in Eastern Nigeria (Igwe, 2015) Hexadecanoic 
acid, methyl ester, is a polyunsaturated fatty acid (PUFA) that has been involved in 
antiplasmodial activity and has been documented to increase with unsaturation, (Melariri et 
al., 2012). The suggested compound 2,4-Di-tert-butylphenol (DTBP) which is 
characteristically volatile is a phenolic compound reported to possess antioxidant properties 
(Choi et al., 2013) and in vitro antimalarial activity at 100 mM (Kusch et al., 2011; 
Kulangara et al., 2015). Furthermore, DTBP isolated from a Lactococcus sp demonstrated 
antifungal, antioxidant and cytotoxicity against cancer cell lines (Jayaseelan et al., 2017). The 
rest of the compounds have not been reported for antimalarial activity but other 
pharmacological importance where Hexatriacontane identified in essential oils of Cassia 
fistula showed significant activity against the standard and clinical isolates of Candida 
species (Irshad et al., 2012). The observed antimalarial efficacy of Lk-3 and by extension the 
other fractions can be attributed to individual or synergistic activity of compounds with 






 CONCLUSION AND RECOMMENDATIONS 
5.1 Conclusion 
Plasmodium resistance to Artemisinin threatens global efforts in the elimination or 
eradication of malaria. Despite past decades of steady advances in the fight against the 
disease, statistics show that the disease is still a threat to public health. The need for 
continued research towards development of new therapies for Malaria cannot be overstated. 
The potential of medicinal plants to serve as the source of the next novel antimalarial drug 
formed the basis of this study. Total organic extracts of Lippia kituiensis were subjected to 
fractionation using Chromatographic techniques. Substantive antimalarial efficacy which was 
more pronounced in-vivo rather than in-vitro was revealed for the first time in this study. The 
in-vitro cytotoxicity results of the fractions of L. kituiensis, suggest their potential safety.  
The classes of compounds attributable to the efficacy have also been made evident in this 
study. Compounds that have been reported previously to possess antimalarial activity were 
identified in the most efficacious fraction (LK-3) from the plant. Therefore, results from this 
study validate traditional use of extracts of the plant to manage malaria. 
5.2 Recommendations 
Based on this study the following recommendations are warranted. Given the revealed 
background antimalarial efficacy of some fractions from L. kituiensis further studies are 
needed in the following areas: 
i) Isolation and purification of novel compound(s) from fractions, particularly Lk-3.  
ii) Screening of compounds isolated from the fractions against Plasmodium parasite 
iii) Comprehensive in-vivo safety studies (sub-acute and chronic toxicity assays) from 
fractions and compounds isolated therefrom. 
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Appendix 1: Antimalarial activity of fractions 
500 mg/kg 
Drug Name Mouse No. RBC PRBC Parasitemia %chemosuppression 
LK-1 1 397 11 2.770780856 74.31883336 
 
1 393 9 2.290076336 78.77427517 
 
1 405 7 1.728395062 83.98025542 
 
1 371 9 2.425876011 77.51560686 
      LK2 2 397 19 4.785894207 55.64162125 
 
2 345 21 6.086956522 43.58263865 
 
2 396 22 5.555555556 48.50796385 
      LK3 3 360 18 5 53.65716746 
 
3 381 16 4.199475066 61.07688606 
 
3 395 12 3.037974684 71.8423296 
 
3 399 15 3.759398496 65.15576501 
      LK4 4 353 21 5.949008499 44.86121908 
 
4 349 17 4.871060172 54.85225484 
 
4 380 20 5.263157895 51.21807102 
 
4 324 17 5.24691358 51.36863252 
      LK5 5 371 14 3.773584906 65.02427733 
 
5 362 17 4.696132597 56.4735827 
 
5 371 15 4.043126685 62.52601143 
 
5 375 14 3.733333333 65.39735171 
 
5 380 17 4.473684211 58.53536036 
      LK6 6 384 22 5.729166667 46.89883772 
 
6 366 19 5.191256831 51.88449081 
 
6 365 20 5.479452055 49.21333421 
 
6 350 23 6.571428571 39.09227724 
      Negative control M1 469 47 10.02132196 0 
 
M2 449 49 10.91314031 0 
 
M3 446 45 10.0896861 0 
 
M4 469 54 11.51385928 0 
 
M5 412 47 11.40776699 0 
      Positive control M1 450 5 1.111111111 89.70159277 
 
M2 436 1 0.229357798 97.87418199 
 




Drug Name Mouse No. RBC PRBC Parasitemia %chemosuppression 
 
M4 478 3 0.627615063 94.18290805 
 
M5 470 1 0.212765957 98.02796457 
 
1000 mg/kg 
Drug Name Mouse No. RBC PRBC %Prasitemia %chemosuppresion 
LK1 1 356 14 3.93258427 73.47116308 
 
1 426 17 3.990610329 73.07972484 
 
1 443 18 4.063205418 72.59000533 
      LK2 2 445 19 4.269662921 71.19726277 
 
2 331 15 4.531722054 69.42943696 
 
2 482 17 3.526970954 76.20739167 
      LK3 3 568 17 2.992957746 79.80979363 
 
3 394 11 2.791878173 81.16625718 
 
3 322 10 3.105590062 79.04998682 
      LK4 4 457 23 5.032822757 66.0490596 
 
4 517 21 4.061895551 72.59884156 
 
4 538 22 4.089219331 72.41451796 
      lk5 5 443 17 3.837471783 74.11278281 
 
5 404 13 3.217821782 78.29288238 
 
5 501 25 4.99001996 66.33780317 
      LK6 6 444 21 4.72972973 68.09369614 
 
6 474 18 3.797468354 74.38264211 
 
6 426 16 3.755868545 74.66327044 
      Negative control 7 412 66 16.01941748 0 
 
7 440 62 14.09090909 0 
 
7 313 47 15.01597444 0 
 
7 367 52 14.16893733 0 
     
0 
Positive control 8 149 2 1.342281879 90.94509497 
 
8 144 2 1.388888889 90.63068855 
 
8 133 1 0.751879699 94.92789155 
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Appendix 2: GC-MS Results 
Library 
Line#:1 R.Time:6.757(Scan#:645) MassPeaks: 304  
RawMode: Averaged 6.751-6.763(644-646) BasePeak:71.05(6109) 







10 40 70 100 130 160 190 220 250 280 310 340 370 400 430 460 490 520 
 
 
Hit#:1 Entry: 29102 Library:NIST14.lib 
SI:77 Formula:C8H14O4 CAS:1117-31-3 MolWeight:174 RetIndex:1087 











Hit#:2 Entry:20017 Library:NIST14.lib 
SI:75 Formula:C9H18O2 CAS:5129-46-4 MolWeight:158 RetIndex:1019 











Hit#:3 Entry:29247 Library:NIST14.lib 
SI:74 Formula:C9H18O3 CAS:204652-53-9  MolWeight:174  RetIndex:1095  












Hit#:4 Entry:13239 Library:NIST14.lib 












Hit#:5 Entry:37228 Library:NIST14.lib 
SI:74 Formula:C11H22O2 CAS:65127-75-5 MolWeight:186 RetIndex:1197 
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OH 
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268  281    297 308     327    347    365 391 417 
445456 468 499     519 543 
<< Target >> 
Line#:2    R.Time:10.770(Scan#:1333)    MassPeaks:273 
RawMode:Averaged 10.764-10.776(1332-1334) BasePeak:191.15(15770) 
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Hit#:1 Entry:51535 Library:NIST14.lib 
SI:96 Formula:C14H22O CAS:96-76-4 MolWeight:206 RetIndex:1555 
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Hit#:2 Entry:51537 Library:NIST14.lib 
SI:91 Formula:C14H22O CAS:128-39-2 MolWeight:206 RetIndex:1555 
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Hit#:3 Entry:51536 Library:NIST14.lib 
SI:90 Formula:C14H22O CAS:1138-52-9 MolWeight:206 RetIndex:1555 
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Hit#:4 Entry:51541 Library:NIST14.lib 
SI:87 Formula:C14H22O CAS:5875-45-6 MolWeight:206 RetIndex:1555 
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Hit#:5 Entry:136853 Library:NIST14.lib 
SI:85 Formula:C19H30O3 CAS:166273-38-7 MolWeight:306 RetIndex:2255 







10 40 70 100 130 160 190 220 250 280 310 340 370 400 430 460 490 520 
<< Target >> 
Line#:3   R.Time:13.418(Scan#:1787)   MassPeaks:303 
RawMode:Averaged 13.413-13.424(1786-1788) BasePeak:58.05(14751) 
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Hit#:1 Entry:102848 Library:NIST14.lib 
SI:95 Formula:C18H36O CAS:502-69-2 MolWeight:268 RetIndex:1754 
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Hit#:2 Entry:90545 Library:NIST14.lib 
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Hit#:3 Entry:203259 Library:NIST14.lib 
SI:82 Formula:C26H50O2 CAS:0-00-0 MolWeight:394 
RetIndex:2878 CompName:Hexacosa-2,25-dione $$ 2,25-











Hit#:4 Entry:45740 Library:NIST14.lib 
SI:82 Formula:C13H26O CAS:1604-34-8 MolWeight:198 RetIndex:1321 











Hit#:5 Entry:56451 Library:NIST14.lib 








20 50 80 110 140 170 200 230 260 290 320 350 380 410 440 470 500 530 
 
 
<< Target >> 
Line#:4   R.Time:14.019(Scan#:1890)   MassPeaks:294 
RawMode:Averaged 14.013-14.025(1889-1891) BasePeak:74.05(20175) 
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Hit#:1 Entry:104648 Library:NIST14.lib 
SI:96 Formula:C17H34O2 CAS:112-39-0 MolWeight:270 RetIndex:1878 
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115 143 199 242 
15 
130 157 171 
185 213 226 
Hit#:2 Entry:104649 Library:NIST14.lib 
SI:91 Formula:C17H34O2 CAS:5129-60-2 MolWeight:270 RetIndex:1814 











Hit#:3 Entry:92472 Library:NIST14.lib 
SI:91 Formula:C16H32O2 CAS:7132-64-1 MolWeight:256 RetIndex:1779 







10 40 70 100 130 160 190 220 250 280 310 340 370 400 430 460 490 520 
 
 
Hit#:4 Entry:117104 Library:NIST14.lib 
SI:90 Formula:C18H36O2 CAS:6929-04-0 MolWeight:284 RetIndex:1914 











Hit#:5 Entry:69324 Library:NIST14.lib 
SI:90 Formula:C14H28O2 CAS:1731-88-0 MolWeight:228 RetIndex:1580 











<< Target >> 
Line#:5   R.Time:14.328(Scan#:1943)   MassPeaks:322 
RawMode:Averaged 14.323-14.334(1942-1944) BasePeak:73.00(16877) 







10 40 70 100 130 160 190 220 250 280 310 340 370 400 430 460 490 520 
 
 
Hit#:1 Entry:80643 Library:NIST14.lib 
SI:92   Formula:C15H30O2   CAS:1002-84-2   MolWeight:242    RetIndex:1869 












Hit#:2 Entry:240687 Library:NIST14.lib 
SI:91 Formula:C38H68O8 CAS:28474-90-0 MolWeight:652 
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127 141 155 169 183 197 211 225 239 253 267 283295 309 323 337 355 368380 396 409 442      467    487 514 531 549 
Hit#:3 Entry:92441 Library:NIST14.lib 
SI:90 Formula:C16H32O2 CAS:57-10-3 MolWeight:256 RetIndex:1968 












Hit#:4 Entry:69322 Library:NIST14.lib 
SI:90 Formula:C14H28O2 CAS:544-63-8 MolWeight:228 RetIndex:1769 











Hit#:5 Entry:117078 Library:NIST14.lib 
SI:89 Formula:C18H36O2 CAS:57-11-4 MolWeight:284 RetIndex:2167 







10 40 70 100 130 160 190 220 250 280 310 340 370 400 430 460 490 520 
 
 
<< Target >> 
Line#:7   R.Time:19.368(Scan#:2807)   MassPeaks:283 
RawMode:Averaged 19.363-19.374(2806-2808) BasePeak:57.05(55797) 











Hit#:1 Entry:233779 Library:NIST14.lib 
SI:96 Formula:C36H74 CAS:630-06-8 MolWeight:506 RetIndex:3600 
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Hit#:2 Entry:115221 Library:NIST14.lib 
SI:96 Formula:C20H42 CAS:112-95-8 MolWeight:282 RetIndex:2009 





































155 169 183 197 211 225 239 253 267 281 295 309 323 337 355 371 394 411 432 448 462 482 496 518 542 
Hit#:3 Entry:239932 Library:NIST14.lib 
SI:95 Formula:C44H90 CAS:7098-22-8 MolWeight:618 RetIndex:4395 











Hit#:4 Entry:229701 Library:NIST14.lib 
SI:95 Formula:C34H70 CAS:14167-59-0 MolWeight:478 RetIndex:3401 











Hit#:5 Entry:237196 Library:NIST14.lib 








20 50 80 110 140 170 200 230 260 290 320 350 380 410 440 470 500 530 560 590 
 
 
<< Target >> 
Line#:8   R.Time:20.378(Scan#:2980)   MassPeaks:322 
RawMode:Averaged 20.372-20.383(2979-2981) BasePeak:57.05(21968) 
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Hit#:1 Entry:239932 Library:NIST14.lib 
SI:96 Formula:C44H90 CAS:7098-22-8 MolWeight:618 RetIndex:4395 







20 50 80 110 140 170 200 230 260 290 320 350 380 410 440 470 500 530 560 590 
 
 
Hit#:2 Entry:233779 Library:NIST14.lib 
SI:94 Formula:C36H74 CAS:630-06-8 MolWeight:506 RetIndex:3600 











Hit#:3 Entry:115221 Library:NIST14.lib 
SI:94 Formula:C20H42 CAS:112-95-8 MolWeight:282 RetIndex:2009 
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155 169 183 197 211 225 239 253 267 281 295 309 323 337 351 365 379 402 420 442 466 489 513 535 
Hit#:4 Entry:238607 Library:NIST14.lib 












Hit#:5 Entry:226987 Library:NIST14.lib 
SI:93 Formula:C33H68 CAS:1720-11-2 MolWeight:464 RetIndex:0 
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<< Target >> 
Line#:9    R.Time:21.597(Scan#:3189)    MassPeaks:318 
RawMode:Averaged 21.591-21.602(3188-3190) BasePeak:57.05(120270) 
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Hit#:1 Entry:233779 Library:NIST14.lib 
SI:96 Formula:C36H74 CAS:630-06-8 MolWeight:506 RetIndex:3600 







20 50 80 110 140 170 200 230 260 290 320 350 380 410 440 470 500 530 560 590 
 
 
Hit#:2 Entry:239932 Library:NIST14.lib 
SI:96 Formula:C44H90 CAS:7098-22-8 MolWeight:618 RetIndex:4395 











Hit#:3 Entry:229701 Library:NIST14.lib 
SI:95 Formula:C34H70 CAS:14167-59-0 MolWeight:478 RetIndex:3401 











Hit#:4 Entry:115221 Library:NIST14.lib 
SI:95 Formula:C20H42 CAS:112-95-8 MolWeight:282 RetIndex:2009 
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127 141 155 169 183 197 211 225 239 253 267 281 295 309 337 365 
Hit#:5 Entry:238607 Library:NIST14.lib 








20 50 80 110 140 170 200 230 260 290 320 350 380 410 440 470 500 530 560 590 
 
 
<< Target >> 
Line#:10  R.Time:23.055(Scan#:3439)  MassPeaks:302 
RawMode:Averaged 23.049-23.061(3438-3440) BasePeak:57.05(19287) 
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Hit#:1 Entry:239932 Library:NIST14.lib 
SI:95 Formula:C44H90 CAS:7098-22-8 MolWeight:618 RetIndex:4395 







20 50 80 110 140 170 200 230 260 290 320 350 380 410 440 470 500 530 560 590 
 
 
Hit#:2 Entry:233779 Library:NIST14.lib 
SI:94 Formula:C36H74 CAS:630-06-8 MolWeight:506 RetIndex:3600 











Hit#:3 Entry:238607 Library:NIST14.lib 













Hit#:4 Entry:195535 Library:NIST14.lib 
SI:93 Formula:C27H56 CAS:1561-02-0 MolWeight:380 RetIndex:0 











Hit#:5 Entry:115221 Library:NIST14.lib 
SI:93 Formula:C20H42 CAS:112-95-8 MolWeight:282 RetIndex:2009 







20 50 80 110 140 170 200 230 260 290 320 350 380 410 440 470 500 530 560 590 






41 99 113 127 
27 





















41 99 113 127 
27 


















127 141 155 169 183 197 
211 225 239 253 267 281 295 309 323 337 351 365 379 393 407 431 452 468 







127 141 155 169 183 197 211 225 239 253 
421 
267   286 323 337 351 365 390 412 437 461 475 490 506 521 545 309 
Line#:11  R.Time:24.846(Scan#:3746)  MassPeaks:332 
RawMode:Averaged 24.840-24.852(3745-3747) BasePeak:57.05(72267) 







20 50 80 110 140 170 200 230 260 290 320 350 380 410 440 470 500 530 560 590 
 
 
Hit#:1 Entry:233779 Library:NIST14.lib 
SI:96 Formula:C36H74 CAS:630-06-8 MolWeight:506 RetIndex:3600 







20 50 80 110 140 170 200 230 260 290 320 350 380 410 440 470 500 530 560 590 
 
 
Hit#:2 Entry:239932 Library:NIST14.lib 
SI:96 Formula:C44H90 CAS:7098-22-8 MolWeight:618 RetIndex:4395 












Hit#:3 Entry:229701 Library:NIST14.lib 
SI:95 Formula:C34H70 CAS:14167-59-0 MolWeight:478 RetIndex:3401 











Hit#:4 Entry:238607 Library:NIST14.lib 













Hit#:5 Entry:115221 Library:NIST14.lib 
SI:94 Formula:C20H42 CAS:112-95-8 MolWeight:282 RetIndex:2009 







20 50 80 110 140 170 200 230 260 290 320 350 380 410 440 470 500 530 560 590 
 
<< Target >> 
Line#:12  R.Time:26.433(Scan#:4018)  MassPeaks:319 
RawMode:Averaged 26.427-26.438(4017-4019) BasePeak:57.05(15755) 




















113 127 141 








141 155 169 183 197 211 



















127 141 155 169 
183 197 211 225 239 253 
282 
